All In Biotech

Drug Trial Radar · NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 31, 2021

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
NIH
First posted
Mar 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.

Conditions

  • Acute Adult T-Cell Leukemia/Lymphoma
  • Adult T-Cell Leukemia/Lymphoma
  • Chronic Adult T-Cell Leukemia/Lymphoma
  • HTLV-1 Infection

Interventions

  • Biospecimen CollectionProcedure

    Undergo tissue and blood sample collection

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Computed TomographyProcedure

    Undergo PET/CT or CT

  • CyclophosphamideDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • EtoposideDrug

    Given IV

  • LenalidomideDrug

    Given PO

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • PrednisoneDrug

    Given PO

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: Up to the end of induction therapy

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center-South County

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Commack

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester

    Harrison, New York · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Suspended

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Suspended

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • NYP/Weill Cornell Medical Center

    New York, New York · Suspended

  • Memorial Sloan Kettering Nassau

    Uniondale, New York · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.